Immatics NV Ordinary Shares IMTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $8.87
- Day Range
- $8.78–9.08
- 52-Week Range
- $5.05–12.41
- Bid/Ask
- $8.50 / $10.96
- Shares Outstanding
- 136.67M
- Market Cap
- $1.24B
- Volume/Avg
- 236,577 / 529,284
Key Statistics
- Price/Earnings (Normalized)
- 847.52
- Price/Sales
- 26.62
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 407
- Website
- https://www.immatics.com
Valuation
|
Metric
|
IMTX
|
|---|---|
Price/Earnings (Normalized) | 847.52 |
Price/Book Value | 2.40 |
Price/Sales | 26.62 |
Price/Cash Flow | — |
Price/Earnings
IMTX
Financial Strength
|
Metric
|
IMTX
|
|---|---|
Quick Ratio | 8.30 |
Current Ratio | 8.78 |
Interest Coverage | −252.73 |
Quick Ratio
IMTX
Profitability
|
Metric
|
IMTX
|
|---|---|
Return on Assets (Normalized) | −31.95% |
Return on Equity (Normalized) | −38.39% |
Return on Invested Capital (Normalized) | −40.03% |
Return on Assets
IMTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Mgxtgxv | Nmhplb | $111B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wyxsnxv | Gkgpcp | $63B | |||
| argenx SE ADR
ARGX
| Kjvjqfm | Mlyc | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qnvhddtx | Ngcnxdp | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Wxmvtqybp | Bdcclkr | $24B | |||
| BioNTech SE ADR
BNTX
| Cwdyndlny | Ntywh | $22B | |||
| Incyte Corp
INCY
| Bzhhqbl | Gkhn | $21B | |||
| Moderna Inc
MRNA
| Sxqbvfvx | Xwzr | $18B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Nyzknbdx | Wgtz | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Jyxsndl | Xjhd | $13B |
United States